Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Control Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

NCT01421498
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

NCT00000912
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
44
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Differences in Effortful Control

NCT01852344
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate, Placebo, Easy Behavioral Task, Hard Behavioral Task
Drug · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 22, 2026, 4:58 AM EDT
Not yet recruiting Not applicable Interventional

Accelerated and Extended-iTBS Targeting Inhibitory Control in Veterans With ADHD

NCT07442058
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Intermittent Theta-Burst Stimulation, Sham Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional

UH3 Phase - Mindfulness-Based Blood Pressure Reduction (MB-BP) : Stage 2a RCT

NCT03859076
View directory record Official record
Conditions
Hypertension, Prehypertension
Interventions
MB-BP, Enhanced Usual Care Control
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional Results available

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

NCT01381718
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
modafinil, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 19 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 4 Interventional

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

NCT00190879
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Comorbid Social Anxiety Disorder
Interventions
Atomoxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Wildomar, California • Bradenton, Florida • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2007 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

NCT01106430
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

NCT01739595
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
enclomiphene citrate, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Mobile, Alabama • Little Rock, Arkansas • Rancho Cucamonga, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00880217
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
35
States / cities
Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transcranial Electrical Stimulation on Task Performance in Healthy Adults

NCT06995560
View directory record Official record
Conditions
Healthy, Brain Stimulation, Transcranial Direct Current Stimulation (tDCS), Cognition, Psychomotor Performance, Neurophysiology
Interventions
Active Transcranial Electrical Stimulation, Sham Transcranial Electrical Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, atomoxetine, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ACtive Children Enhance LEaRning and AttenTION: A Randomized Controlled Trial (RCT)

NCT05794360
View directory record Official record
Conditions
Physical Inactivity
Interventions
ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
8 Years to 11 Years
Enrollment
257 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

NCT00857090
View directory record Official record
Conditions
Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones
Interventions
OMS201, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orange, California • Denver, Colorado • Nasville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 4 Interventional Results available

Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting

NCT01986062
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
AR11, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Bradenton, Florida • Maitland, Florida • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Results available

Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study

NCT00689091
View directory record Official record
Conditions
Awareness During General Anesthesia
Interventions
Bispectral Index Monitor, Electronic MAC alert
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
22,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Double-Blind Randomized Controlled Trial for the Evaluation of a Novel Adaptive Attention Training in Healthy Adolescents

NCT03213613
View directory record Official record
Conditions
Healthy Adolescents
Interventions
Adaptive Attention Training, Active Control, Low-dose Adaptive Attention Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 22, 2026, 4:58 AM EDT
Recruiting Phase 4 Interventional

Effect of Local Anesthetic Concentration on Rebound Pain

NCT07146685
View directory record Official record
Conditions
Rebound Pain, Shoulder Arthroplasty, Interscalene Block
Interventions
Bupivacaine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
ABT-894, atomoxetine, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
San Francisco, California • Wildomar, California • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Oct 22, 2026, 4:58 AM EDT
Completed Not applicable Interventional

Early Family-Centered Prevention of Drug Use Risk (Aka Early Steps)

NCT01098695
View directory record Official record
Conditions
Substance Use, Conduct Disorder, Depression, Anxiety
Interventions
Ecological Family Intervention and Treatment (EcoFIT)
Other
Lead sponsor
University of Oregon
Other
Eligibility
2 Years to 3 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
3
States / cities
Eugene, Oregon • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 22, 2026, 4:58 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

NCT04419272
View directory record Official record
Conditions
Epilepsy
Interventions
Methylphenidate, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 4:58 AM EDT